Maze Therapeutics (MAZE), a clinical stage biopharmaceutical company, has drawn investor attention after recent trading. The stock last closed at $29.30 and has shown mixed returns over the past week and month.

Looking beyond the latest move to $29.30, Maze Therapeutics has seen a 14.10% 1 month share price return and a 10.57% 3 month share price return, while its year to date share price return is down 26.33% and the 1 year total shareholder return is 72.96%. This suggests earlier momentum has eased recently.

If Maze Therapeutics is on your radar for high risk, high reward ideas in healthcare, it can be useful to compare it with other fast moving opportunities in the sector via the 39 healthcare AI stocks.

After Maze Therapeutics jumped to $29.30 yet remains down for the year, some investors may see urgency while others prefer to wait for a pullback. How does the current valuation stack up against that trade off?

Preferred Price to Book Multiple of 4.7x: Is it justified?

On simple balance sheet terms, Maze Therapeutics currently trades at a P/B of 4.7x, which sets a clear marker against both peers and the wider market.

The P/B ratio compares Maze Therapeutics's market value with the book value of its net assets, which can be a useful reference point for a clinical stage biopharmaceutical company that is still loss making. For a business with no current profits, investors often look at asset backing and funding structure alongside the development pipeline.

There are two contrasting valuation signals in the data. On one hand, Maze Therapeutics is described as good value versus its peer group average P/B of 32x, which is a very large premium to its own multiple. On the other hand, the stock is described as expensive compared with the broader US pharmaceuticals industry P/B of 2.4x, suggesting investors are currently paying a higher price per dollar of net assets than the sector overall.

This split picture implies the market is assigning Maze Therapeutics a premium relative to the wider industry, while still pricing it well below a narrower set of peers that trade on much richer P/B levels.

Result: Price-to-book of 4.7x (ABOUT RIGHT)

However, investors should keep in mind that Maze Therapeutics is still loss making, with a net loss of $122.542 million and reliance on successful clinical trial progress.

Next Steps

With Maze Therapeutics showing both pressure from recent losses and interest around its potential, it makes sense to check the underlying data rather than rely on headlines alone. If you want to weigh the trade off between its key concerns and potential positives for yourself, start with the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Maze Therapeutics?

If Maze Therapeutics has caught your interest, do not stop there. Broaden your watchlist with focused stock ideas that fit different risk and income profiles.

• Target potential mispricing by reviewing companies that screen as overlooked value opportunities using the 50 high quality undervalued stocks.
• Strengthen your income focus by scanning for companies offering robust payouts through the 9 dividend fortresses.
• Prioritize capital protection by assessing companies highlighted as resilient using the 81 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.